F-1/A: Akanda Corp Eyes Expansion with Proposed Securities Offering

Akanda Corp plans to offer up to 85,365,854 common shares and pre-funded warrants to raise capital for various corporate purposes.

Summary

• Akanda Corp, a cannabis cultivation, manufacturing, and distribution company, is planning a public offering.
• The offering includes up to 85,365,854 common shares and pre-funded warrants.
• Pre-funded warrants are offered in lieu of common shares to investors whose ownership would exceed 4.99% or 9.99% of outstanding shares after the offering.
• The purchase price of each pre-funded warrant is the price of a common share less $0.0001, with an exercise price of $0.0001 per share.
• The company intends to use the net proceeds for capital expenditures, operating capacity, working capital, general corporate purposes, refinancing existing debt, and potential acquisitions.
• Akanda Corp is organized under the laws of the Province of Ontario, Canada and is an emerging growth company and a foreign private issuer.
• The offering price will be determined through negotiation between the company and the underwriters.
• The company's common shares are currently quoted on the Nasdaq Capital Market under the symbol AKAN.
• The company is following shareholder voting rules in accordance with the laws in the Province of Ontario, Canada, for transactions other than public offerings as defined under The Nasdaq Stock Market rules.

Sentiment

Score: 4

Explanation: The document is primarily a registration statement for a securities offering, which is inherently neutral. However, the inclusion of risk factors and the company's limited operating history temper any positive sentiment.

Positives

• The company has the option to follow certain Canadian corporate governance practices, which may provide flexibility in its operations.
• The company intends to use the net proceeds for capital expenditures, operating capacity, working capital, general corporate purposes, refinancing existing debt, and potential acquisitions.

Negatives

• Investing in the company's securities is highly speculative and involves a high degree of risk.
• The company has a limited operating history and minimal revenues to date.
• The company is subject to risks associated with conducting business outside of the United States.
• The company may not be able to maintain a listing of its Common Shares on Nasdaq.

Risks

• The company's limited operating history and minimal revenues to date pose a risk to its financial stability.
• Changes in cannabis laws, regulations, and guidelines could adversely affect the company's business.
• The company faces potential exposure to product liability claims and actions.
• The company's ability to raise capital and the availability of future financing are uncertain.
• The company's ability to maintain the listing of its securities on Nasdaq is not guaranteed.
• The company is subject to risks associated with conducting business outside of the United States.

Future Outlook

The company aims to become a market leader in the cultivation, processing, and supply of medicinal-grade cannabis products for international markets, with a focus on expanding its distribution network in the UK and pursuing accretive acquisitions.

Industry Context

The company is targeting the international medical cannabis market, which is estimated to be worth approximately $47 billion by 2027. The company believes there has been a growing demand for medical cannabis around the world as a result of the increased legalization of cannabis for medical purposes as well as the rise in cannabis -related medical research activities.

Legal Proceedings

• Tejinder Virk issued a claim for Detriment and dismissal for alleged protected disclosures totaling 1,630,302.22. The claim has been denied in its entirety.
• Louisa Mojela filed a claim against Canmart and Akanda for wrongful termination of her Service Agreement. Ms. Mojelas entire application failed and Canmart and Akanda were awarded 60,000 in legal costs. Ms. Mojela is pursuing an appeal.
• Trevor Scott filed a claim against the Company for amounts owing under his employment agreement totaling 420,659.95. This claim was resolved via a confidential settlement on January 15, 2024 and no amounts beyond this settlement are further owing to Mr. Scott.

Related Party Transactions

• The company has incurred aggregated outstanding loans, including accrued interest, of approximately $1,429,092 from Halo (the Halo Debt), making Halo a significant creditor of the Company.
• There may be an inherent conflict of interest because our interim Chief Executive Officer and director, Ms. Katie Field, is serving as the Chief Executive Officer and Chairman of Halo.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution in the book value of their investment.
• The company's ability to raise capital and the availability of future financing are uncertain, which could impact its ability to execute its business plan.

Next Steps

• The company plans to expand its relationships with premium product suppliers to bring safe, effective and required products to market that patients demand, and working with existing and new clinical cannabis operations in the United Kingdom to provide third party products.
• The company plans to continue selling premium high potency EU GMP certified flower.
• The company plans to expand markets for distribution outside of the European Union.
• The company plans to obtain licenses for THC cultivation, CBD cultivation, and hemp cultivation.

Key Dates

Keywords

common shares, pre-funded warrants, public offering, capital raise, cannabis, Akanda Corp, securities, medical